UK markets close in 7 hours 35 minutes
  • FTSE 100

    7,113.04
    -55.64 (-0.78%)
     
  • FTSE 250

    22,729.31
    -183.42 (-0.80%)
     
  • AIM

    1,192.80
    -3.25 (-0.27%)
     
  • GBP/EUR

    1.1742
    +0.0017 (+0.14%)
     
  • GBP/USD

    1.3301
    +0.0023 (+0.18%)
     
  • BTC-GBP

    42,892.50
    -201.46 (-0.47%)
     
  • CMC Crypto 200

    1,452.52
    -16.56 (-1.13%)
     
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • DOW

    34,022.04
    -461.68 (-1.34%)
     
  • CRUDE OIL

    66.61
    +1.04 (+1.59%)
     
  • GOLD FUTURES

    1,771.70
    -12.60 (-0.71%)
     
  • NIKKEI 225

    27,753.37
    -182.25 (-0.65%)
     
  • HANG SENG

    23,788.93
    +130.01 (+0.55%)
     
  • DAX

    15,282.84
    -189.83 (-1.23%)
     
  • CAC 40

    6,792.82
    -89.05 (-1.29%)
     

Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Evercore ISI 4th Annual HealthCONx Conference. Freeline Chief Executive Officer Michael Parini is scheduled to participate in a Fireside Chat at the event on December 2, 2021 at 3:55 p.m. EST.

A webcast of the Fireside Chat will be available on the Investors section of the Freeline website for approximately 90 days. Senior management will participate in virtual one-on-one meetings with investors throughout the conference.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Contact

David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting